Arbutus Biopharma Corporation - Common Stock (ABUS)
4.7000
-0.0500 (-1.05%)
NASDAQ · Last Trade: Mar 5th, 5:12 PM EST
Detailed Quote
Previous Close
4.750
Open
4.660
Bid
4.680
Ask
4.690
Day's Range
4.660 - 4.810
52 Week Range
2.705 - 5.100
Volume
2,543,902
Market Cap
466.06M
PE Ratio (TTM)
-20.43
EPS (TTM)
-0.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,733,248
Chart
About Arbutus Biopharma Corporation - Common Stock (ABUS)
Arbutus Biopharma Corp is a biotechnology company focused on developing innovative therapies for viral infections, particularly those caused by the hepatitis B virus (HBV). The company is engaged in the discovery and development of a range of novel compounds aimed at addressing unmet medical needs in the treatment of chronic viral diseases. Arbutus employs a diverse approach to its research and development efforts, including the utilization of RNA interference technology and other mechanisms to advance its therapeutic candidates. Through its commitment to scientific excellence, Arbutus aims to provide effective treatment options that can significantly improve the lives of patients affected by viral infections. Read More
In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant Sciences and Arbutus Biopharma (NASDAQ:ABUS). Announced on March 3, 2026, the deal concludes one of the most contentious patent
BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax®.
BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant, and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax®.
As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based pioneer is currently undergoing a painful but essential metamorphosis. The "mRNA 1.0" era, defined by the singular success of its COVID-19 vaccine, has effectively ended. [...]
Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period characterized by a sharp decline from its 2021 peak market valuation of nearly $190 billion, the Cambridge-based pioneer is working to convince a skeptical [...]
As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the biotechnology giant is now grappling with a stock price that has settled into a volatile range between $33.
Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the early 2020s, the Cambridge-based pioneer has spent the last 24 months attempting to shed its image as a "pandemic-only" play. After [...]
WARMINSTER, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a corporate update.
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company’s Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company’s board of directors.
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon
Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the third largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published a letter to the Company’s Board of Directors (the “Board”) outlining its views on the actions Arbutus must take in order to preserve and maximize shareholder value.
